{
  "guideline": {
    "id": "PA166182823",
    "name": "Annotation of DPWG Guideline for eliglustat and CYP2D6",
    "source": "DPWG",
    "version": 12,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182823",
    "relatedChemicals": [
      {
        "id": "PA166123486",
        "name": "eliglustat",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302370",
      "name": "Recommendation Annotation PA166302370",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103949,
        "html": "<p>Eliglustat is contra-indicated. Choose an alternative if possible.</p>\n"
      },
      "implications": [
        "This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302361",
      "name": "Recommendation Annotation PA166302361",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103940,
        "html": "<p>The guideline does not provide a recommendation for eliglustat in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on eliglustat."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302365",
      "name": "Recommendation Annotation PA166302365",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103944,
        "html": "<p>The guideline does not provide a recommendation for eliglustat in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on eliglustat."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302321",
      "name": "Recommendation Annotation PA166302321",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103900,
        "html": "<p>Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR:</p>\n<ul>\n<li>Eliglustat is contra-indicated. Choose an alternative if possible.</li>\n</ul>\n<p><em>Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.</em></p>\n<p>Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):</p>\n<ul>\n<li>Use a dose of 84mg eliglustat 1x daily.</li>\n</ul>\n<p>Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):</p>\n<ul>\n<li>Consider a dose of 84mg eliglustat 1x daily. Be alert to side effects.</li>\n</ul>\n<p>Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):</p>\n<ul>\n<li>Choose an alternative if possible.</li>\n<li>If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.</li>\n</ul>\n<p>Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):</p>\n<ul>\n<li>Choose an alternative.</li>\n<li>If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.</li>\n</ul>\n<p>Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.</p>\n<ul>\n<li>Choose an alternative if possible.</li>\n</ul>\n<p>NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:</p>\n<ul>\n<li>Use the standard dose of 84mg 2x daily.</li>\n</ul>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302369",
      "name": "Recommendation Annotation PA166302369",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103948,
        "html": "<p>Eliglustat is contra-indicated. Choose an alternative if possible.</p>\n"
      },
      "implications": [
        "This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302373",
      "name": "Recommendation Annotation PA166302373",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103952,
        "html": "<p>Eliglustat is contra-indicated. Choose an alternative if possible.</p>\n"
      },
      "implications": [
        "This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302364",
      "name": "Recommendation Annotation PA166302364",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103943,
        "html": "<p>The guideline does not provide a recommendation for eliglustat in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on eliglustat."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302368",
      "name": "Recommendation Annotation PA166302368",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103947,
        "html": "<p>Eliglustat is contra-indicated. Choose an alternative if possible.</p>\n"
      },
      "implications": [
        "This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302372",
      "name": "Recommendation Annotation PA166302372",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103951,
        "html": "<p>Eliglustat is contra-indicated. Choose an alternative if possible.</p>\n"
      },
      "implications": [
        "This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302288",
      "name": "Recommendation Annotation PA166302288",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103867,
        "html": "<p>Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):</p>\n<ul>\n<li>Eliglustat is contra-indicated. Choose an alternative if possible.</li>\n</ul>\n<p>Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):</p>\n<ul>\n<li>Eliglustat is not recommended. Choose an alternative if possible.</li>\n</ul>\n<p>Co-medication with a WEAK CYP3A INHIBITOR (for example amlopidine, cilostazole, fluvoxamine, goldenseal, isoniazide, ranitidine, ranolazine):</p>\n<ul>\n<li>Choose an alternative for the weak CYP3A inhibitor if possible.</li>\n<li>If an alternative is not an option: Use a dose of 84mg eliglustat 1x daily and be alert to side effects.</li>\n</ul>\n<p>Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum):</p>\n<ul>\n<li>Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.</li>\n<li>Choose an alternative if possible.</li>\n</ul>\n<p>NO co-medication with a CYP3A inhibitor or strong CYP3A inducer:</p>\n<ul>\n<li>Use a dose of 84mg 1x daily.</li>\n</ul>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of eliglustat to inactive metabolites. This increases the risk of side effects, such as a (small, dose-dependent) elongation of the QT interval. CYP3A inhibitors increase this risk even further."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302363",
      "name": "Recommendation Annotation PA166302363",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103942,
        "html": "<p>The guideline does not provide a recommendation for eliglustat in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on eliglustat."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302341",
      "name": "Recommendation Annotation PA166302341",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103920,
        "html": "<p>Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR:</p>\n<ul>\n<li>Eliglustat is contra-indicated. Choose an alternative if possible.</li>\n</ul>\n<p><em>Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.</em></p>\n<p>Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):</p>\n<ul>\n<li>Use a dose of 84mg eliglustat 1x daily.</li>\n</ul>\n<p>Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):</p>\n<ul>\n<li>Consider a dose of 84mg eliglustat 1x daily. Be alert to side effects.</li>\n</ul>\n<p>Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):</p>\n<ul>\n<li>Choose an alternative if possible.</li>\n<li>If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.</li>\n</ul>\n<p>Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):</p>\n<ul>\n<li>Choose an alternative.</li>\n<li>If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.</li>\n</ul>\n<p>Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.</p>\n<ul>\n<li>Choose an alternative if possible.</li>\n</ul>\n<p>NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:</p>\n<ul>\n<li>Use the standard dose of 84mg 2x daily.</li>\n</ul>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302367",
      "name": "Recommendation Annotation PA166302367",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103946,
        "html": "<p>Eliglustat is contra-indicated. Choose an alternative if possible.</p>\n"
      },
      "implications": [
        "This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302301",
      "name": "Recommendation Annotation PA166302301",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103880,
        "html": "<p>Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR:</p>\n<ul>\n<li>Eliglustat is contra-indicated. Choose an alternative if possible.</li>\n</ul>\n<p><em>Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.</em></p>\n<p>Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):</p>\n<ul>\n<li>Use a dose of 84mg eliglustat 1x daily.</li>\n</ul>\n<p>Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):</p>\n<ul>\n<li>Consider a dose of 84mg eliglustat 1x daily. Be alert to side effects.</li>\n</ul>\n<p>Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):</p>\n<ul>\n<li>Choose an alternative if possible.</li>\n<li>If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.</li>\n</ul>\n<p>Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):</p>\n<ul>\n<li>Choose an alternative.</li>\n<li>If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.</li>\n</ul>\n<p>Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.</p>\n<ul>\n<li>Choose an alternative if possible.</li>\n</ul>\n<p>NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:</p>\n<ul>\n<li>Use the standard dose of 84mg 2x daily.</li>\n</ul>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302371",
      "name": "Recommendation Annotation PA166302371",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103950,
        "html": "<p>Eliglustat is contra-indicated. Choose an alternative if possible.</p>\n"
      },
      "implications": [
        "This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302362",
      "name": "Recommendation Annotation PA166302362",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103941,
        "html": "<p>The guideline does not provide a recommendation for eliglustat in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on eliglustat."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302366",
      "name": "Recommendation Annotation PA166302366",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103945,
        "html": "<p>Eliglustat is contra-indicated. Choose an alternative if possible.</p>\n"
      },
      "implications": [
        "This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302322",
      "name": "Recommendation Annotation PA166302322",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103901,
        "html": "<p>Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR:</p>\n<ul>\n<li>Eliglustat is contra-indicated. Choose an alternative if possible.</li>\n</ul>\n<p><em>Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.</em></p>\n<p>Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):</p>\n<ul>\n<li>Use a dose of 84mg eliglustat 1x daily.</li>\n</ul>\n<p>Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):</p>\n<ul>\n<li>Consider a dose of 84mg eliglustat 1x daily. Be alert to side effects.</li>\n</ul>\n<p>Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):</p>\n<ul>\n<li>Choose an alternative if possible.</li>\n<li>If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.</li>\n</ul>\n<p>Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):</p>\n<ul>\n<li>Choose an alternative.</li>\n<li>If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.</li>\n</ul>\n<p>Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.</p>\n<ul>\n<li>Choose an alternative if possible.</li>\n</ul>\n<p>NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:</p>\n<ul>\n<li>Use the standard dose of 84mg 2x daily.</li>\n</ul>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2023-12-19-10-38"
}